30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Bone Therapeutics’ ALLOB Achieves Primary Endpoint in Delayed-Union Fracture Study -

Bone Therapeutics reported all patients met the primary endpoint in the U.S. Phase I/IIA study of ALLOB® allogeneic bone-cell therapy in the treatment of delayed-union fractures. The company’s next priority is submitting an application for a Phase IIB trial in delayed-union fractures. The multi-center, randomized, controlled study is expected to begin in 2H19. (Bone Therapeutics, 9/14/18)